Key Points
- Director Arnold Hanish sold 5,000 Omeros shares at an average price of $18.53, generating $92,650 and reducing his position by 50% to 5,000 shares.
- Omeros recently reported stronger-than-expected quarterly results, with earnings of $0.02 per share versus consensus expectations for a $0.27 loss and revenue of $28.53 million.
- The stock opened at $18.61 and has a “Moderate Buy” analyst consensus, with an average price target of $38.00; institutional investors own 48.79% of the company.
Omeros Corporation (NASDAQ:OMER - Get Free Report) Director Arnold Hanish sold 5,000 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $18.53, for a total value of $92,650.00. Following the completion of the sale, the director owned 5,000 shares of the company's stock, valued at approximately $92,650. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Omeros Stock Performance
Omeros stock opened at $18.61 on Friday. The stock's 50 day moving average price is $12.64 and its 200 day moving average price is $12.03. The firm has a market capitalization of $1.35 billion, a PE ratio of 14.54 and a beta of 2.54. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65.
Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analysts' expectations of $12.69 million. On average, analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Zacks Research downgraded shares of Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. Finally, Weiss Ratings upgraded shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $38.00.
Read Our Latest Stock Report on Omeros
Institutional Trading of Omeros
Institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its stake in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 800 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 1,004 shares during the last quarter. State of Wyoming bought a new stake in shares of Omeros in the 4th quarter worth about $25,000. AQR Capital Management LLC increased its position in shares of Omeros by 7.2% in the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 1,532 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Omeros by 12.1% in the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company's stock valued at $261,000 after purchasing an additional 1,637 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.
About Omeros
(
Get Free Report)
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
